Cannabis Law Report
MARCH 23, 2022
Psychedelic medicine could provide much needed treatment options for some mental health and neurological disorders in the near future. However, our drug laws impede research and deny patients access to these highly effective medicines. Further research is essential before PAP can become a medicine available on the NHS.
Cannabis Law Report
MARCH 1, 2019
Natalie has worked with private hospitals and clinics in relation to medical malpractice claims, and assisted on cases involving medical devices product liability and clinical trials. Whilst legalised nearly four months ago, so far virtually no-one in the UK has actually been able to obtain a prescription for medicinal cannabis.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
SEPTEMBER 22, 2021
A Home Office spokesperson said: “There is an established process for the development of medicines, which enables medicines including psilocybin to be developed, evaluated in clinical trials and licensed based on an assessment of their quality, safety and efficacy. Source: [link].
The Cannigma
MAY 19, 2021
In 2019, Japan approved clinical trials for Epidiolox — a cannabis derived medicine used to treat severe forms of childhood epilepsy such as Dravet and Lennox-Gastaut syndromes. In 2018, Epidolex became the first plant-derived cannabinoid prescription medicine to receive FDA approval.
Cannabis Law Report
APRIL 8, 2019
Through the Narcotic Drugs Amendment Act 2016 (Cth) and its amendments to the Narcotic Drugs Act 1967 (Cth) ( NDA ), the Australian Government commenced the legalisation of medicinal cannabis products in Australia under federal law in 2016. Australia’s medicinal cannabis industry continues to flourish. Chapter 2 of the NDA.
Cannabis Law Report
AUGUST 2, 2021
(OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain.
The Cannigma
JANUARY 13, 2023
For example, researchers at Hopkins Medicine point to changes in chemical compounds like CGRP , serotonin and hormones like estrogen affecting pain levels. The Cleveland Clinic estimates around 12% of Americans suffer from migraine disorders, and is the 6 th most disabling disease worldwide.
Expert insights. Personalized for you.
52 
Let's personalize your content